XTL Biopharmaceuticals Ltd.
XTLBHealthcare|Biotechnology|IL
$1.55
-0.16 (-9.36%)
Cash / Share
$0.02
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT00553592 Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes | Diabetic Peripheral Neuropathy | P2 | Unknown | 336 | RCT, Double-blind | Bicifadine, Bicifadine, Bicifadine |
| NCT00597649 A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Chronic Peripheral Neuropathy Pain in Diabetics | P2 | Terminated | 250 | RCT, Open-label | Bicifadine |
| NCT00300807 Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection | Hepatitis C | P1 | Unknown | 36 | RCT, Double-blind | XTL 6865 |
| NCT00255359 Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers | Chronic Hepatitis C Virus Infection | P1 | Withdrawn | 60 | RCT, Double-blind | XTL-2125 |